IGC Pharma, Inc. 8-K

What Happened IGC Pharma, Inc. (IGC) filed a Form 8-K on June 8, 2026, reporting that it entered an amendment to its Master Loan and Security Agreement and General Banking Facility Letter with O-Bank Co., Ltd. The amendment continues the facility arrangement originally set by the June 24, 2025 facility letter and maintains substantially the same material terms. The amendment is filed as Exhibit 10.1 to the 8-K.

Key Details

• Lender: O-Bank Co., Ltd. (Taiwan-based banking corporation).
• Facility size: Maximum aggregate limit of $12,000,000.
• Fee change: Facility fee increased from $48,000 to $60,000 (an increase of $12,000).
• Terms: Material terms otherwise remain substantially unchanged from the 2025 facility letter; the amendment creates a direct financial obligation for the company.

Why It Matters This amendment preserves IGC’s access to up to $12.0 million in borrowing capacity under the renewed banking facility, which can affect the company’s liquidity and financing options. The increase in the facility fee raises the company’s non-interest cost under the agreement by $12,000 versus the prior fee. Investors should watch subsequent filings for any draws on the facility, interest rate or covenant details, and how the company uses the available funds.